Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

mAbs

Volumn 6, Issue 5, 2014, Pages 1133-1144

  Meyer, Saskia ^a   Leusen, Jeanette H W ^a   Boross, Peter ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CLUSTERIN; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT FACTOR H; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY; VITRONECTIN;

CANCER IMMUNOTHERAPY; CANCER PATIENT; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DNA POLYMORPHISM; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; PROTEIN FUNCTION; REVIEW;

EID: 84913603159     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.29670     Document Type: Review

References (119)

1. Beers SA, Cragg MS, Glennie MJ. Complement: help or hindrance? Blood 2009; 114:5567-8, author reply 5568; PMID:20035044; http://dx.doi.org/10.1182/ blood-2009-10-249466
2. Introna M, Golay J. Complement in antibody therapy: friend or foe? Blood 2009; 114:5247-8; PMID:20018922; http://dx.doi.org/10.1182/blood-2009-10-249532
3. Taylor RP, Lindorfer MA. The role of complement in mAb-based therapies of cancer. Methods 2014; 65:18-27; PMID:23886909; http://dx.doi.org/ 10.1016/j.ymeth.2013.07.027
4. Macor P, Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett 2007; 111:6-13; PMID:17572509; http://dx.doi.org/ 10.1016/j.imlet.2007.04.014
5. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol 2014; 32:433-59; PMID:24499275; http://dx.doi. org/10.1146/annurev-immunol-032713-120154
6. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010; 9:43-56; PMID:19960015; http://dx.doi.org/ 10.1038/nrd3011
7. Gelderman KA, Lam S, Sier CF, Gorter A. Crosslinking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity. Eur J Immunol 2006; 36:977-84; PMID:16525993; http://dx.doi.org/ 10.1002/eji.200535653
8. Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011; 96:1822-30; PMID:21880632; http://dx.doi.org/10.3324/ haematol.2011.047159
9. Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE, Gessner JE. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 2002; 110:1823-30; PMID: 12488432; http://dx.doi.org/10.1172/JCI16577
10. Chen CH, Boackle RJ. A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses. Clin Immunol Immunopathol 1998; 87:68-74; PMID: 9576012; http://dx.doi.org/10.1006/clin.1997.4515
11. Bowen B, Hawk JJ, Sibunka S, Hovick S, Weiler JM. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin Immunol 2001; 98:157-63; PMID:11161971; http:// dx.doi.org/10.1006/clim.2000.4947
12. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15:69-78; PMID:19162547; http://dx. doi.org/10.1016/j.molmed.2008.12.001
13. Rodr-?guez de C-ordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, S-anchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41:355-67; PMID:15163532; http:// dx.doi.org/10.1016/j.molimm.2004.02.005
14. Kopp A, Hebecker M, Svobodov-a E, J-ozsi M, Factor H. A Complement Regulator in Health and Disease, and a Mediator of Cellular Interactions. Biomolecules 2012; 2:46-75; http://dx.doi.org/10.3390/biom2010 046
15. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor Hlike protein 1. J Immunol 2000; 164:6075-81; PMID:10820293; http://dx.doi.org/10.4049/jimmu nol.164.11.6075
16. Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, et al. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol 2012; 87:880-5; PMID:22718493; http://dx.doi.org/ 10.1002/ajh.23273
17. Blom AM, Bergstrom F, Edey M, Diaz-Torres M, Kavanagh D, Lampe A, Goodship JA, Strain L, Moghal N, McHugh M, et al. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol 2008; 180:6385-91; PMID:18424762; http://dx.doi.org/10.4049/jimmu nol.180.9.6385
18. Murphy BF, Saunders JR, O'Bryan MK, Kirszbaum L, Walker ID, d'Apice AJ. SP-40,40 is an inhibitor of C5b-6-initiated haemolysis. Int Immunol 1989; 1:551-4; PMID:2489042; http://dx.doi.org/10.1093/ intimm/1.5.551
19. Hochgrebe TT, Humphreys D, Wilson MR, Easter-brook-Smith SB. A reexamination of the role of clusterin as a complement regulator. Exp Cell Res 1999; 249:13-21; PMID:10328949; http://dx.doi.org/10.10 06/excr.1999.4459
20. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991; 88:1924-32; PMID:1721625; http://dx.doi. org/10.1172/JCI115516
21. Liu D, Niu ZX. The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35). Immunopharmacol Immunotoxicol 2009; 31:524-35; PMID:19874218; http://dx.doi.org/10.3109/08923 970902845768
22. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumano-glu MH, Kavukcu S, Filler G, Pirson Y, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003; 100:12966-71; PMID:14566051; http://dx. doi.org/10.1073/pnas.2135497100
23. Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol 2009; 46:2774-83; PMID:19481265; http://dx.doi.org/10.1016/j.molimm.2009.04.029
24. Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjørge L, Butzow R, Zipfel PF, Meri S. Secretion of soluble complement inhibitors factor H and factor Hlike protein (FHL-1) by ovarian tumour cells. Br J Cancer 2002; 87:1119-27; PMID:12402151; http:// dx.doi.org/10.1038/sj.bjc.6600614
25. Ajona D, Castaño Z, Garayoa M, Zudaire E, Pajares MJ, Martinez A, Cuttitta F, Montuenga LM, Pio R. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 2004; 64:6310-8; PMID:15342420; http://dx.doi.org/10.1158/0008-5472.CAN-03-2328
26. Wilczek E, Rzepko R, Nowis D, Legat M, Golab J, Glab M, Gorlewicz A, Konopacki F, Mazurkiewicz M, Sladowski D, et al. The possible role of factor H in colon cancer resistance to complement attack. Int J Cancer 2008; 122:2030-7; PMID:18183578; http:// dx.doi.org/10.1002/ijc.23238
27. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM, Sensibar JA. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997; 3:1707-11; PMID:9815554
28. Parczyk K, Pilarsky C, Rachel U, Koch-Brandt C. Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 1994; 120:186-8; PMID:8263017; http://dx.doi.org/10.1007/BF01202200
29. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001; 61:3869-76; PMID: 11358798
30. Kumar S, Vinci JM, Pytel BA, Baglioni C. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 1993; 53:348-53; PMID:7678074
31. Behrens P, Jeske W, Wernert N, Wellmann A. Downregulation of clusterin expression in testicular germ cell tumours. Pathobiology 2001; 69:19-23; PMID: 11641613; http://dx.doi.org/10.1159/000048753
32. Redondo M, Villar E, Torres-Muñoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000; 157: 393-9; PMID:10934144; http://dx.doi.org/10.1016/ S0002-9440(10)64552-X
33. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002; 34:1430-48; PMID:12200037; http://dx.doi. org/10.1016/S1357-2725(02)00041-9
34. Yasumitsu H, Seo N, Misugi E, Morita H, Miyazaki K, Umeda M. Vitronectin secretion by hepatic and non-hepatic human cancer cells. In Vitro Cell Dev Biol Anim 1993; 29A:403-7; PMID:7686142; http:// dx.doi.org/10.1007/BF02633989
35. Kadowaki M, Sangai T, Nagashima T, Sakakibara M, Yoshitomi H, Takano S, Sogawa K, Umemura H, Fushimi K, Nakatani Y, et al. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. J Cancer Res Clin Oncol 2011; 137:1105-15; PMID:21253 761; http://dx.doi.org/10.1007/s00432-010-0974-9
36. Seya T, Matsumoto M, Hara T, Hatanaka M, Masaoka T, Akedo H. Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies. Leuk Lymphoma 1994; 12:395-400; PMID:7514063; http://dx.doi.org/10.3109/ 10428199409073780
37. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996; 149:129-42; PMID:8686736
38. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 2003; 131:254-63; PMID:12562385; http://dx. doi.org/10.1046/j.1365-2249.2003.02066.x
39. Coral S, Fonsatti E, Sigalotti L, De Nardo C, Visintin A, Nardi G, Colizzi F, Colombo MP, Romano G, Altomonte M, et al. Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. J Cell Physiol 2000; 185:317-23; PMID:11056001; http:// dx.doi.org/10.1002/1097-4652(200012)185:3<317:: AID-JCP1>3.0.CO;2-L
40. Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG. Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol 2003; 200:633-9; PMID:12898600; http://dx.doi.org/ 10.1002/path.1357
41. Koretz K, Bruderlein S, Henne C, Moller P. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 1993; 68:926-31; PMID:7692919; http://dx. doi.org/10.1038/bjc.1993.456
42. Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 2006; 8:69-78; PMID:16533428; http:// dx.doi.org/10.1593/neo.05679
43. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 2003; 52:638-42; PMID: 12811528; http://dx.doi.org/10.1007/s00262-003-0402-y
44. Blok VT, Daha MR, Tijsma OM, Weissglas MG, van den Broek LJ, Gorter A. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab Invest 2000; 80:335-44; PMID:10744069; http://dx.doi. org/10.1038/labinvest.3780038
45. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-54; PMID:12393572; http://dx.doi.org/ 10.1182/blood-2002-02-0469
46. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98:3383-9; PMID:11719378; http://dx.doi. org/10.1182/blood.V98.12.3383
47. Inoue T, Yamakawa M, Takahashi T. Expression of complement regulating factors in gastric cancer cells. Mol Pathol 2002; 55:193-9; PMID:12032231; http://dx.doi.org/10.1136/mp.55.3.193
48. Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB, Martens MG, Kaul A. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 2000; 76:176-82; PMID: 10637067; http://dx.doi.org/10.1006/gyno.1999. 5614
49. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104:1793-800; PMID:15172969; http://dx. doi.org/10.1182/blood-2004-01-0039
50. Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, Golay J. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013; 190:231-9; PMID:23225880; http://dx.doi.org/10.4049/ jimmunol.1202645
51. Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma 2012; 53:2218-27; PMID:22475085; http:// dx.doi.org/10.3109/10428194.2012.681657
52. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186:3762-9; PMID:21296976; http://dx.doi.org/ 10.4049/jimmunol.1000303
53. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004; 89:1476-83; PMID:15590398
54. Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM, Schichman SA. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004; 28:495-507; PMID:15068903; http://dx.doi.org/10.1016/j.leukres. 2003.09.011
55. Hale G, Swirsky DM, Hayhoe FG, Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1983; 1:321-34; PMID:6438435
56. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73:1431-9; PMID:2713487
57. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186:1840-8; PMID: 21187443; http://dx.doi.org/10.4049/jimmunol.100 3032
58. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, Haas KM, Tedder TF. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008; 112:1205-13; PMID:18495955; http://dx.doi.org/10.1182/ blood-2008-01-135160
59. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-69; PMID:15210744; http://dx.doi.org/ 10.1084/jem.20040119
60. Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, Ahuja A, Shlomchik MJ, Cragg MS, Glennie MJ. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximablike) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112:4170-7; PMID:18583569; http://dx.doi.org/10.1182/blood-2008-04-149161
61. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115:5191-201; PMID:202239 20; http://dx.doi.org/10.1182/blood-2010-01-2635 33
62. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009; 128:260-70; PMID:19740383; http://dx.doi.org/ 10.1111/j.1365-2567.2009.03115.x
63. Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RH, van de Winkel JG, van Egmond M. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol 2008; 181:6829-36; PMID:18981101; http://dx.doi.org/ 10.4049/jimmunol.181.10.6829
64. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171:1581-7; PMID:12874252; http://dx.doi.org/10.4049/jimmu nol.171.3.1581
65. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103:2738-43; PMID:14551143; http:// dx.doi.org/10.1182/blood-2003-06-2031
66. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 2005; 65:10562-8; PMID: 16288049; http://dx.doi.org/10.1158/0008-5472. CAN-05-1894
67. Boross P, Jansen JH, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011; 96:1822-30; PMID:21880632; http://dx.doi.org/10.3324/ haematol.2011.047159
68. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20C cells by rituximab. Blood 2003; 101:1071-9; PMID:12393727; http://dx.doi.org/10.1182/blood-2002-03-0876
69. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012; 188:3532-41; PMID:22368276; http://dx.doi.org/10.4049/ jimmunol.1103693
70. Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann N Y Acad Sci 2009; 1173:865-73; PMID:19758239; http://dx.doi.org/ 10.1111/j.1749-6632.2009.04803.x
71. Xu W, Miao KR, Zhu DX, Fang C, Zhu HY, Dong HJ, Wang DM, Wu YJ, Qiao C, Li JY. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer 2011; 128:2192-201; PMID:20635386; http://dx.doi.org/10.1002/ ijc.25560
72. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008; 111:1456-63; PMID:18024795; http://dx.doi. org/10.1182/blood-2007-02-074716
73. Kern DJ, James BR, Blackwell S, Gassner C, Klein C, Weiner GJ. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma 2013; 54:2500-5; PMID: 23452151; http://dx.doi.org/10.3109/10428194. 2013.781169
74. Wang SY, Veeramani S, Racila E, Cagley J, Fritzinger DC, Vogel CW, St John W, Weiner GJ. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009; 114:5322-30; PMID:19805620; http://dx.doi.org/ 10.1182/blood-2009-01-200469
75. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008; 14:6697-703; PMID:18927313; http:// dx.doi.org/10.1158/1078-0432.CCR-08-0745
76. Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG, Maio M. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 1996; 74:33-42; PMID:8569195
77. Beyer I, Cao H, Persson J, Wang H, Liu Y, Yumul R, Li Z, Woodle D, Manger R, Gough M, et al. Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques. Mol Ther 2013; 21:291-9; PMID: 23089733; http://dx.doi.org/10.1038/mt.2012.212
78. Varsano S, Rashkovsky L, Shapiro H, Radnay J. Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines. Am J Respir Cell Mol Biol 1998; 19:522-9; PMID:9730881; http://dx.doi.org/10.1165/ajrcmb. 19.3.3181
79. Blok VT, Gelderman KA, Tijsma OH, Daha MR, Gorter A. Cytokines affect resistance of human renal tumour cells to complement-mediated injury. Scand J Immunol 2003; 57:591-9; PMID:12791098; http:// dx.doi.org/10.1046/j.1365-3083.2003.01265.x
80. Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, Schultz S, Kirschfink M. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets 2010; 10:922-31; PMID:20879979; http://dx.doi.org/ 10.2174/156800910793357952
81. Terui Y, Sakurai T, Mishima Y, Mishima Y, Sugimura N, Sasaoka C, Kojima K, Yokoyama M, Mizunuma N, Takahashi S, et al. Blockade of bulky lymphomaassociated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 2006; 97:72-9; PMID:16367924; http://dx.doi.org/10.1111/j.1349-7006.2006.00139.x
82. Mamidi S, Cinci M, Hasmann M, Fehring V, Kirschfink M. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances com-plement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol Oncol 2013; 7:580-94; PMID:23474221; http://dx.doi.org/10.1016/j. molonc.2013.02.011
83. Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 2011; 71:2298-307; PMID:21252115; http:// dx.doi.org/10.1158/0008-5472.CAN-10-3016
84. Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 2011; 17:6702-11; PMID:21918174; http://dx.doi.org/10.1158/1078-0432.CCR-11-0647
85. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95:3900-8; PMID:10845926
86. Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35:2175-83; PMID: 15971270; http://dx.doi.org/10.1002/eji.200425920
87. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67:10556-63; PMID:17975000; http://dx.doi.org/10.1158/0008-5472.CAN-07-1811
88. Gelderman KA, Blok VT, Fleuren GJ, Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 2002; 82:483-93; PMID:11950905; http://dx. doi.org/10.1038/labinvest.3780441
89. Gelderman KA, Kuppen PJ, Bruin W, Fleuren GJ, Gorter A. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur J Immunol 2002; 32:128-35; PMID:11754353; http://dx.doi.org/10.1002/ 1521-4141(200201)32:1< 128::AID-IMMU128>3. 0.CO;2-P
90. Gelderman KA, Kuppen PJ, Okada N, Fleuren GJ, Gorter A. Tumor-specific inhibition of membranebound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res 2004; 64:4366-72; PMID: 15205353; http://dx.doi.org/10.1158/0008-5472. CAN-03-2131
91. Horl S, Banki Z, Huber G, Ejaz A, Mullauer B, Willenbacher E, Steurer M, Stoiber H. Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica 2013; 98:1939-47; PMID:23850806; http://dx. doi.org/10.3324/haematol.2013.089615
92. Horl S, B-anki Z, Huber G, Ejaz A, Windisch D, Muellauer B, Willenbacher E, Steurer M, Stoiber H. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia 2013; 27:2200-8; PMID:23760402; http://dx.doi.org/ 10.1038/leu.2013.169
93. Lindorfer MA, Beum PV, Taylor RP. CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I. Antibodies 2013; 2:598-616; http://dx.doi. org/10.3390/antib2040598
94. Miwa T, Song WC. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol 2001; 1:445-59; PMID:11367529; http://dx.doi.org/ 10.1016/S1567-5769(00)00043-6
95. Ong GL, Mattes MJ. Mouse strains with typical mammalian levels of complement activity. J Immunol Methods 1989; 125:147-58; PMID:2607149; http:// dx.doi.org/10.1016/0022-1759(89)90088-4
96. Gerritsen AF, Bosch M, de Weers M, de Winkel JG, Parren PW. High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging. J Immunol Methods 2010; 352:140-6; PMID:19891971; http://dx.doi.org/ 10.1016/j.jim.2009.10.009
97. Rosner T, Derer S, Kellner C, Dechant M, Lohse S, Vidarsson G, Peipp M, Valerius T. An IgG3 switch variant of rituximab mediates enhanced complementdependent cytotoxicity against tumour cells with low CD20 expression levels. Br J Haematol 2013; 161:282-6; PMID:23294176; http://dx.doi.org/ 10.1111/bjh.12209
98. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2011; 2:599; PMID:22186895; http://dx. doi.org/10.1038/ncomms1608
99. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, Wakitani M, Ohta S, Satoh M, Shitara K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68:3863-72; PMID:18483271; http:// dx.doi.org/10.1158/0008-5472.CAN-07-6297
100. Thommesen JE, Michaelsen TE, Løset GA, Sandlie I, Brekke OH. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. Mol Immunol 2000; 37:995-1004; PMID:11395138; http://dx.doi.org/10.1016/S0161-5890(01)00010-4
101. Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166:2571-5; PMID: 11160318; http://dx.doi.org/10.4049/jimmunol. 166.4.2571
102. Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010; 2:181-9; PMID:20150767; http://dx.doi.org/ 10.4161/mabs.2.2.11158
103. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 2002; 8:1720-30; PMID:12060609
104. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, et al. Comple-ment-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008; 68:4998-5003; PMID:18593896; http://dx.doi.org/10.1158/0008-5472.CAN-07-6226
105. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343:1260-3; PMID:24626930; http://dx.doi. org/10.1126/science.1248943
106. Beurskens FJ, de Jong RN, Verploegen S, Voorhorst M, Strumane K, Lindorfer MA, Taylor RP, Saphire EO, Burton D, Schuurman J, et al. Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma. Blood 2013; 122:375.
107. Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995; 32:1311-8; PMID:8643100; http:// dx.doi.org/10.1016/0161-5890(95)00118-2
108. Tsuchiya N, Endo T, Matsuta K, Yoshinoya S, Aikawa T, Kosuge E, Takeuchi F, Miyamoto T, Kobata A. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol 1989; 16:285-90; PMID:2498512
109. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995; 1:237-43; PMID:7585040; http://dx.doi.org/ 10.1038/nm0395-237
110. Wright A, Morrison SL. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 1998; 160:3393-402; PMID:9531299
111. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/ 10.1074/jbc.M202069200
112. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A 2007; 104:8433-7; PMID:17485663; http://dx.doi.org/ 10.1073/pnas.0702936104
113. Reiter Y, Fishelson Z. Targeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. J Immunol 1989; 142:2771-7; PMID:2522969
114. Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel CW. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F (ab')2-cobra venom factor conjugate are equally cytotoxic. Mol Immunol 1990; 27:957-64; PMID: 2233757; http://dx.doi.org/10.1016/0161-5890(90) 90118-J
115. Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel CW. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiology 1997; 197:444-59; PMID:9413745; http://dx.doi.org/ 10.1016/S0171-2985(97)80078-2
116. Xiang D, Sharma VR, Freter CE, Yan J. Anti-tumor monoclonal antibodies in conjunction with b-glucans: a novel anti-cancer immunotherapy. Curr Med Chem 2012; 19:4298-305; PMID:22834812; http://dx.doi. org/10.2174/092986712802884303
117. Imai M, Ohta R, Varela JC, Song H, Tomlinson S. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res 2007; 67:9535-41; PMID:17909064; http://dx.doi.org/10.1158/0008-5472.CAN-07-1690
118. Elvington M, Huang Y, Morgan BP, Qiao F, van Rooijen N, Atkinson C, Tomlinson S. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood 2012; 119:6043-51; PMID:22442351; http://dx.doi.org/ 10.1182/blood-2011-10-383232
119. Boross P, Leusen JH. Boosting antibody therapy with complement. Blood 2012; 119:5945-7; PMID: 22730521; http://dx.doi.org/10.1182/blood-2012-04-420760